⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NTRA News
Natera, Inc. Common Stock
Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study
businesswire.com
NTRA
Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio
businesswire.com
NTRA
Global Non-Invasive Prenatal Testing Market Report — Just Released; Comprehensive 181-Page Analysis with Broad Product and Application Scope
globenewswire.com
RVTY
ILMN
NTRA
QGEN
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
businesswire.com
NTRA
Form 8-K
sec.gov
NTRA
Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer
businesswire.com
NTRA
Oncology Precision Medicine Market Trends & Opportunities Forecast 2021-2031
globenewswire.com
AMRX
NTRA
Minimal Residual Disease Testing Market Size to Reach USD 7.97 Billion by 2035 at 11.50% CAGR | Industry Report by SNS Insider
globenewswire.com
ABT
NTRA
GRDX
LH
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer
businesswire.com
NTRA
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
businesswire.com
NTRA